Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caribou Biosciences Inc (NQ: CRBU )

5.715 -0.095 (-1.64%)
Streaming Delayed Price Updated: 1:33 PM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 549,248
Open 5.770
Bid (Size) 5.710 (8)
Ask (Size) 5.720 (14)
Prev. Close 5.810
Today's Range 5.535 - 5.770
52wk Range 3.440 - 8.650
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool

Performance

YTD
-13.54%
-13.54%
1 Month
+48.44%
+48.44%
3 Month
-10.56%
-10.56%
6 Month
+23.17%
+23.17%
1 Year
-29.96%
-29.96%

More News

Read More
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Where Caribou Biosciences Stands With Analysts
Via Benzinga
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
2 Top Growth Stocks to Buy Right Now Without Hesitation
Via The Motley Fool
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
From Caribou Biosciences, Inc.
Via GlobeNewswire
2 Exciting Biotech Stocks to Buy With Less Than $10
Via The Motley Fool
Big Pharma Could Transform Into BioTech Pharma
Via Benzinga
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
Via The Motley Fool
2 Magnificent Growth Stocks to Buy On the Dip
Via The Motley Fool
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
From Caribou Biosciences, Inc.
Via GlobeNewswire
1 Gene Editing Stock to Buy Now, and 1 to Sell
Via The Motley Fool
Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday
Via Benzinga
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
3 Clever Tricks to Find Winning Biotech Stocks
Via The Motley Fool
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond
Via The Motley Fool
NXP Semiconductors To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
This 1 Innovation Could Make These 2 Biotechs Soar by 2030
Via The Motley Fool
Got $1,000? Buying Caribou Biosciences Stock Right Now Could Be a Brilliant Move in 5 Years
Via The Motley Fool
2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.